| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.0003 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |